Provisional Conference Program

Wednesday 7th September 2005

SESSION 7:
NEW ADJUVANTS/DRUGS FOR CANCER VACCINES
Moderator: Joyce-Taylor-Papadimitriou (Cancer Research UK, London, UK)

08.30-09.00
‘Vaccine adjuvants to improve cancer control’
David B. Hoon (John Wayne Cancer Institute, Santa Monica, USA)

09.00-09.30
‘IC31 – a promising adjuvant candidate for use in peptide-based cancer vaccines’
Karen Lingnau (Intercell AG, Vienna, Austria)

09.30-09.50
‘Recombinant human IL-18 as immunotherapeutic agent in cancer’
Danuta Herzyk, Jeanne Soos, Mohammed Dar and Zdenka Jonak (GlaxoSmithKline Pharmaceuticals, King-of-Prussia, Pennsylvania, USA)

09.50-10.10
‘Evaluation of anti tumor efficacy of high density expression of cancer peptides and immunomodulators on the surface of the bacterium caulobacter crescentus’
J. Smit, J.N. Nomellini, P.K. Bhatnagar, A. Awasthi and M.R. Suresh (University of British Columbia, Vancouver, Canada)

10.10-10.30
‘Epitope-drug conjugates in the targeted immunotherapy of B-cell leukemias’
Michael A. Firer (College of Judea and Samaria, Ariel. Israel)

10.30-11.00
Coffee Break & Posters

SESSION 8:
NEW DELIVERY SYSTEMS FOR CANCER VACCINES
Moderator: John Samuel (University of Alberta, Canada)

11.00-11.30
‘Nanoparticulate delivery of cancer vaccines’
John Samuel (University of Alberta, Canada)

11.30-11.50
‘Immunostimulatory colloidal delivery systems for cancer vaccines’
S. Hook, D. Lendemans, T. Hennessy, W. McBurney and T. Rades (University of Otago, Dunedin, New Zealand)

11.50-12.10
‘Pre-clinical and clinical results from targeting gangliosides in breast cancer: the more abundant NacGM3 vs the tumour-specific NGcGM3’
L.E. Fernandez, A de la Torre, R. Lazo, M. Labrada, G. Saurwz, Y. Bebelagua, E. Santiesteban, M.C. Arango, A. Carr and R. Perez (Centre of Molecular Immunology, Havana, Cuba)

12.10-14.00
Lunch Break & Posters

SESSION 8 (Continued) & LATE BREAKERS:
Moderator: Dave Hoon (John Wayne Cancer Institute, USA)

14.00-14.30
‘Anticancer activity of mycobacterial cell wall-DNA complex (MCC): immune stimulant, immune adjuvant and direct anticancer activities’
Mario C. Filion and Nigel C. Phillips (Bioniche Inc., Montreal, Canada)

14.30-14.50
‘Delivery of tumour antigens and cytotoxic T cell epitopes using a membrane translocating peptide induces cellular and protective immune responses’
Dodie S. Pouniotis, Geoffrey A. Pietersz, Peter J. VanMannen, Rene W. Andriessen, Jodie Lodding, Pei-xiang Xing, Ian F.C. McKenzie, Bruce E. Loveland and Vasso Apostolopoulos (The Austin Research Institute, Heidelberg, Victoria, Australia)

14.50-15.10
‘Particulate structures of the VP1-coat protein of murine polyomavirus: Immunostimulatory carriers for the efficient delivery of CD8 T cell epitopes derived from tumour antigens’
Juergen Hess, Marc Brinkman, Torsten W. Schulz and Christian Reiser (Responsif GmbH, Erlangen, Germany)

15.10-15.30
‘Open label phase II studies of Modified Vaccine Ankara (MVA) expressing the tumor antigen 5T4 given in conjunction with 5-FU based chemotherapies: safety and immunogenicity before, during and after chemotherapy’
Richard Harrop et al. (Oxford BioMedica U.K. Ltd, Oxford, UK)

15.30-15.50
‘Particulate structures of the VP1-coat protein of murine polyomavirus: Immunostimulatory carriers for the efficient delivery of CD8 T cell epitopes derived from tumour antigens’
Z. Zakay-Rones et al. (Hebrew University, Jerusalem, Israel)

15.50-16.20
Tea Break & Posters Breakdown

SESSION 9:
CLOSING PLENARY SESSION
Moderator: Hans Strander (Karolinska Instutute, Stockholm, Sweden)

16.20-16.40
‘Regulatory Issues for Cancer Vaccines’
Thea Sesardic (NIBSC, Potter Bar, UK)

16.40-17.10
‘Future developments and prospects for cancer vaccines’
Daniel E. Speiser (Ludwig Institute, Lausanne, Switzerland)

17.10-17.15
Closing Remarks